Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Technology appraisal guidance
Reference number: TA261
Published: 25 July 2012

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: ERG's response to Bayer's comment on the ACD

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: ERG's response to Bayer's comment on the ACD

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: ERG's response to Bayer's comment on the ACD
01 June 2012
(462.89 Kb 14 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 28 May 2012